Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: GlaxoSmithKline Clear all
Completed Phase 3 Interventional

Patients With Epilepsy Taking LAMICTAL Immediate-Release Who Switch To Extended-Release Formulation And Vice Versa

NCT00264615
View directory record Official record
Conditions
Epilepsy
Interventions
lamotrigine extended-release
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
13 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
12
States / cities
Anniston, Alabama • Sun City, Arizona • Lexington, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 3 Interventional Results available

COREG MR Versus TOPROL-XL On The Lipid Profile Of Normolipidemic Or Mildly Dyslipidemic Patients With Hypertension

NCT00273052
View directory record Official record
Conditions
Hypertension
Interventions
Carvedilol Phosphate modified release formulation, metoprolol succinate
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
102
States / cities
Birmingham, Alabama • Montgomery, Alabama • Chandler, Arizona + 84 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2018 · Synced Jul 23, 2026, 2:10 PM EDT
Active, not recruiting Phase 2 Interventional

Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant

NCT04876248
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Belantamab Mafodotin, Lenalidomide
Biological · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Eltrombopag/Boceprevir and Eltrombopag/Telaprevir Drug-Drug Interaction Study In Healthy Adult Subjects

NCT01657552
View directory record Official record
Conditions
Thrombocytopaenia
Interventions
Eltrombopag, Boceprevir, Telaprevir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 12, 2017 · Synced Jul 23, 2026, 2:10 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Sumatriptan 4 mg Statdose in the Acute Treatment of Cluster Headache

NCT00399243
View directory record Official record
Conditions
Episodic Cluster Headache, Chronic Cluster Headache
Interventions
Sumatriptan 4mg Statdose injection
Drug
Lead sponsor
Diamond Headache Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 1, 2009 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014

NCT00614614
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix), GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix), Infanrix®, ActHIB®, Pediarix®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
1,558 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
56
States / cities
Birmingham, Alabama • Dothan, Alabama • Benton, Arkansas + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 3 Interventional Results available

The Effect Of Oral Ibandronate In Male Osteoporosis

NCT00397839
View directory record Official record
Conditions
Male Osteoporosis
Interventions
Ibandronate, placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
30 Years and older · Male only
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
41
States / cities
Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 36 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2009 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Early Phase 1 Interventional Results available

Mepolizumab for the Treatment of Chronic Spontaneous Urticaria

NCT03494881
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Nucala
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine

NCT04707391
View directory record Official record
Conditions
Meningitis, Meningococcal
Interventions
MenABCWY vaccine, Placebo, MenACWY vaccine, MenB vaccine
Combination Product · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
15 Years to 25 Years
Enrollment
1,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
48
States / cities
Jonesboro, Arkansas • Banning, California • Chula Vista, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 1 Interventional

Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors

NCT00732420
View directory record Official record
Conditions
Solid Tumours
Interventions
topotecan, pazopanib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 12, 2017 · Synced Jul 23, 2026, 2:10 PM EDT
Terminated Phase 2 Interventional Results available

Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403

NCT00655824
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
ofatumumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
4
States / cities
Los Angeles, California • Fort Lauderdale, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Not applicable Interventional

Coping Peer Intervention for Adherence

NCT01169883
View directory record Official record
Conditions
Asthma
Interventions
Coping Peer Support, Doctor Asthma Messages, Coping Peer Asthma Messages, Asthma Supervision, Music Tracks
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
11 Years to 16 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 2 Interventional Results available

Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT01243190
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Ofatumumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 2 Interventional Results available

A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients

NCT02202161
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK2330672, Placebo, Sitagliptin, Metformin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 64 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Chula Vista, California • Miami, Florida • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 1 Interventional

Dose-Escalation Study of GSK2126458

NCT00972686
View directory record Official record
Conditions
Solid Tumours
Interventions
GSK2126458
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
7
States / cities
San Francisco, California • New Brunswick, New Jersey • Chapel Hill, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Jul 23, 2026, 2:10 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biomarkers in Nasal Samples of Seasonal Allergic Rhinitics

NCT04670627
View directory record Official record
Conditions
Seasonal Allergic Rhinitis, Rhinovirus
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Jul 23, 2026, 2:10 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects.

NCT01283100
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus I
Interventions
GSK1349572, GSK2248761
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 4 Interventional Results available

Phase 4 Fluticasone Furoate Nasal Spray (VERAMYST) Long Term Pediatric Growth Study.

NCT00570492
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Fluticasone furoate nasal spray, Placebo nasal spray
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 8 Years
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
50
States / cities
Oxford, Alabama • Little Rock, Arkansas • Huntington Beach, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 1 Interventional

The Effects Of GW679769 (Casopitant) On The Pharmacokinetics Of Docetaxel In Subjects With Cancer

NCT00440128
View directory record Official record
Conditions
Nausea and Vomiting, Chemotherapy-Induced
Interventions
Docetaxel, Casopitant/Docetaxel
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
4
States / cities
Hot Springs, Arkansas • Iowa City, Iowa • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Jul 23, 2026, 2:10 PM EDT
Completed No phase listed Observational

Study of Subjects With Diabetic Foot Ulcer (DFU)

NCT03153007
View directory record Official record
Conditions
Diabetic Foot
Interventions
Not listed
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2018 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Utility of Versican and Hyaluronan Measurement in Induced Sputum as Biomarkers of Asthma

NCT00980707
View directory record Official record
Conditions
Allergic Asthma
Interventions
Inhaled corticosteroid (fluticasone)
Drug
Lead sponsor
Associated Scientists to Help Minimize Allergies
Other
Eligibility
18 Years to 45 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 18, 2012 · Synced Jul 23, 2026, 2:10 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Ambrisentan in Children 8-18yrs

NCT01332331
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Ambrisentan - low dose, Ambrisentan - high dose
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
8 Years to 18 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Aurora, Colorado • Boston, Massachusetts • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 2 Interventional

A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Persistent Asthma.

NCT00398645
View directory record Official record
Conditions
Asthma
Interventions
GW685698X 200mcg,GW685698X 200mcg and 400mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
648 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
16
States / cities
Fullerton, California • Huntington Beach, California • Orange, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Jul 23, 2026, 2:10 PM EDT
Recruiting Early Phase 1 Interventional

A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases

NCT07268053
View directory record Official record
Conditions
Glioblastoma (GBM), Brain Metastasases
Interventions
Risvutatug rezetecan
Drug
Lead sponsor
Nader Sanai
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jul 23, 2026, 2:10 PM EDT